

## Referenties werking en effecten anabole steroïden

1. Andrews MA, Magee CD, Combest TM, Allard RJ, Douglas KM. Physical Effects of Anabolic-androgenic Steroids in Healthy Exercising Adults: A Systematic Review and Meta-analysis. *Current sports medicine reports*. 2018;17(7):232-41.
2. Woerdeman J, de Ronde W. Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. *Expert Opinion on Investigational Drugs*. 2011;20(1):87-97.
3. Horwitz H, Andersen J, Dalhoff K. Health consequences of androgenic anabolic steroid use. *Journal of internal medicine*. 2019;285(3):333-40.
4. Pope Jr HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. *Endocrine reviews*. 2013;35(3):341-75.
5. Handelsman DJ, Hirschberg AL, Bermon S. Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance. *Endocrine Reviews*. 2018;39(5):803-29.
6. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. *Fertility and sterility*. 2014;101(5):1271-9.
7. Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. *Addiction*. 2015;110(5):823-31.
8. Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, et al. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. *PLOS ONE*. 2016;11(8):e0161208.
9. Flanagan J, Lehtihet M. The response to gonadotropin-releasing hormone and hCG in men with prior chronic androgen steroid abuse and clinical hypogonadism. *Hormone and Metabolic Research*. 2015;47(09):668-73.
10. Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. *Sports Medicine*. 2017;47(9):1869-83.
11. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. *Drug and Alcohol Dependence*. 2010;109(1):6-13.
12. Westerman ME, Charchenko CM, Ziegelmann MJ, Bailey GC, Nippoldt TB, Trost L. Heavy testosterone use among bodybuilders: an uncommon cohort of illicit substance users. *Mayo Clinic Proceedings*. 2016;91(2):175-82.
13. Cohen J, Collins R, Darkes J, Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. *Journal of the International Society of Sports Nutrition*. 2007;4(1):12.
14. Smit D, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. *The Netherlands Journal of Medicine*. 2018:167.

# MAINline

DRUGS & GEZONDHEID

15. Ljungdahl S, Ehrnborg C, Eriksson B, Lindqvist Bagge A, Mo-berg T. Patients who Seek Treatment for AAS Abuse in Sweden: Description of Characteristics. *Substance Pattern and Mortality Rate J Addict Med Ther.* 2019;3(11).
16. Begley E, McVeigh J, Hope V. Image and Performance Enhancing Drugs National Survey Results. Public Health Institute, Liverpool John Moores University; 2017.
17. Lee S, Lee YB, Choe SJ, Lee W-S. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. *Acta dermato-venereologica.* 2019;99(1-2):12-7.
18. Schwingel PA, Cotrim HP, dos Santos Jr CR, Dos Santos AO, de Andrade ARCF, Carruego MVVB, et al. Recreational anabolic-androgenic steroid use associated with liver injuries among Brazilian young men. *Substance use & misuse.* 2015;50(11):1490-8.
19. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. *Circulation.* 2017;135(21):1991-2002.
20. Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Ulriksen PS, et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. *American Heart Journal.* 2018;203:49-56.
21. Hernández-Guerra AI, Tapia J, Menéndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. *Forensic Sciences Research.* 2019;4(3):267-73.
22. Fett WCR. Blood Biochemical Markers of Competitive Bodybuilding Athletes Users of Anabolic Androgenic Steroids and/or Growth Hormone (AAS/GH), Strength Athletes Drugs Free and Sedentary Persons. 2018.
23. Gheshlaghi F, Piri-Ardakani M-R, Masoumi GR, Behjati M, Paydar P. Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences.* 2015;20(2):165.
24. Li M, Rabkin S. Extremely Low HDL Cholesterol and Increased LDL Cholesterol Induced by the use of Anabolic Steroids in a Body Builder: A Case Study. *Int J Sports Exerc Med.* 2018;4(109).
25. Chin-Yee B, Lazo-Langner A, Butler-Foster T, Hsia C, Chin-Yee I. Blood donation and testosterone replacement therapy. *Transfusion.* 2017;57(3):578-81.
26. Emamian M, Hasanian SM, Tayefi M, Bijari M, Movahedian Far F, Shafiee M, et al. Association of hematocrit with blood pressure and hypertension. *Journal of clinical laboratory analysis.* 2017;31(6).
27. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. *Jama.* 1989;261(8):1165-8.
28. Reddy Kilim S, Chandala SR. A comparative study of lipid profile and oestradiol in pre- and post-menopausal women. *J Clin Diagn Res.* 2013;7(8):1596-8.
29. Sudhir K, Komesaroff PA. Cardiovascular Actions of Estrogens in Men. *The Journal of Clinical Endocrinology & Metabolism.* 1999;84(10):3411-5.
30. Gates MA, Mekary RA, Chiu GR, Ding EL, Wittert GA, Araujo AB. Sex Steroid Hormone Levels and Body Composition in Men. *The Journal of Clinical Endocrinology & Metabolism.* 2013;98(6):2442-50.

# MAINline

## DRUGS & GEZONDHEID

31. Sahebkar A, Serban M-C, Penson P, Gurban C, Ursoniu S, Toth PP, et al. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. *Drugs*. 2017;77(11):1187-97.
32. Kosmas CE, Sourlas A, Mallarkey G, Silverio D, Ynoa DY, Montan PD, et al. Therapeutic management of hyperlipoproteinemia (a). *Drugs in context*. 2019;8.
33. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. *The Lancet*. 2006;367(9520):1412-20.
34. Karavolos S, Reynolds M, Panagiotopoulou N, McEleny K, Scally M, Quinton R. Male central hypogonadism secondary to exogenous androgens: a review of the drugs and protocols highlighted by the online community of users for prevention and/or mitigation of adverse effects. *Clinical endocrinology*. 2015;82(5):624-32.
35. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. *Fertil Steril*. 2009;91(4 Suppl):1427-30.
36. Gruber AJ, Pope Jr HG. Psychiatric and medical effects of anabolic-androgenic steroid use in women. *Psychotherapy and psychosomatics*. 2000;69(1):19-26.
37. Tircova B, Bosakova Z, Kozlik P. Development of an ultra-high performance liquid chromatography-tandem mass spectrometry method for the determination of anabolic steroids currently available on the black market in the Czech Republic and Slovakia. *Drug Test Anal*. 2018.
38. de Hon O, van Kleij R. Kwaliteit van illegale dopingmiddelen. Een inventarisatie van de kwaliteit van illegaal verhandelde dopinggeduide middelen en de gezondheidsrisico's bij gebruik Capelle aan den IJssel: Nederlands Centrum voor Dopingvraagstukken. 2005.
39. Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, et al. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013. *Journal of acquired immune deficiency syndromes (1999)*. 2016;71(3):331-7.
40. Ip EJ, Yadao MA, Shah BM, Lau B. Infectious disease, injection practices, and risky sexual behavior among anabolic steroid users. *AIDS care*. 2016;28(3):29